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In mammalian lung, at the transition to extrauterine life, NO/cGMP signal transduction system is known to play crucial roles in
theregulationofvascular resistanceandissupposedtoactinangiogenesis. PDE5,whichisthemostabundantcGMPmetabolizing
enzymewithinthelung,ishighlyexpressedintheperinatalperiod,butitslocalisationinthediﬀerentpulmonarycellsisstillpoorly
known. In our research, PDE5 immunohistochemical distribution was investigated in foetal and neonatal rat lung. The highest
expression of PDE5 was found in cells randomly located in the stroma; in newborns, in particular, many cells in the intersaccular
walls were heavily labelled, while much lower staining levels were shown by smooth myocytes belonging to vessels and airways.
On the basis of their immunoreactivity for α-SM actin and/or desmin, most of the heavily PDE5-positive cells were identiﬁed as
interstitial myoﬁbroblasts and transitional pericytes, while only a few were interpreted as interstitial lipoﬁbroblasts.
Copyright © 2009 Angela Scipioni et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
In mammals, pulmonary vascular resistance is known to be
modulated by cGMP, which induces relaxation of vascular
smooth muscle through the activation of cGMP-dependent
protein kinases. In smooth muscle cells, cGMP is synthesised
by nitric oxide- and natriuretic peptide-activated guanylate
cyclases, while its degradation occurs through phospho-
diesterases. Among the eleven phosphodiesterase families
recognised in mammalian tissues [1], cGMP-binding cGMP-
speciﬁc phosphodiesterase (PDE5) shows particularly strong
enzymaticactivitiesinhighlyvascularizedorgans,suchasthe
lungs and the spleen [2–4]. Moreover, its mRNA and protein
were speciﬁcally detected in vascular smooth muscle cells; so
that the enzyme is supposed to play a key role in inducing
vessel relaxation.
Inadultratlungs,PDE5ishighlyconcentratedinsmooth
muscle cells in the medial layer of pulmonary arteries and
veins [5] and its expression increases in hypoxia-induced
pulmonary hypertension [6]. Moreover, in rodents as well
as in humans, PDE5 speciﬁc inhibitors such as zaprinast
and sildenaﬁl markedly attenuate hypertension itself [5, 7];
consequently these substances, together with other agents
that modulate intracellular cGMP, are considered as promis-
ing, safe, and easy-to-administer therapies for pulmonary
hypertension [8].
During the perinatal reorganization of the pulmonary
vascular bed, when both constitutive endothelial nitric oxide
synthase and soluble guanylate cyclase are highly expressed
[9, 10], alterations in PDE5 activity, protein, and mRNA
w e r ed e s c r i b e db o t hi no v i n ea n di nr o d e n tl u n g s[ 11, 12].
Moreover, increases of soluble guanylate cyclase and PDE5
were found in lambs with pulmonary hypertension [13]a n d
zaprinast and sildenaﬁl were eﬀective in lowering pulmonary
vascularresistanceofnormalandhypertensiveovinefoetuses
[14–16]. In hyperoxia-exposed rat pups, sildenaﬁl, besides
alleviating pulmonary hypertension, interestingly, increased
pulmonary capillary density and preserved alveolar growth;
preservation of endothelial network during hyperoxia was
also found in vitro [17]. It was therefore suggested that
the beneﬁcial eﬀects on vascular and alveolar growth might
occur through promotion of lung angiogenesis.
Although sildenaﬁl appears as a promising agent for
the management of pulmonary hypertension [18], several2 Journal of Biomedicine and Biotechnology
issues need to be addressed before advocating the clinical
use of this and others PDE5 inhibitors. In order to evaluate
their side eﬀects, the distribution of the enzyme in the
organs and in the diﬀerent cell types inside the organs
must be extensively described. Indeed, in many organs,
P D E 5w a sf o u n dt ob ee x p r e s s e db yc e l lt y p e sd i ﬀerent
from smooth muscle cells, for example, Purkinje cells
[19], platelets, epithelia of renal proximal tubules and
collecting ducts, as well as pancreatic duct cells [20, 21].
In adult rat lungs, the enzyme was immunolocalised in
the smooth muscle of vessels and airways, including the
alveolar ducts and openings of the alveoli; its expression
was found to accompany the distal muscularization of
pulmonary arterioles, pathognomonic of hypoxia-induced
pulmonary hypertension [5–22]. In newborn rat lungs,
PDE5 mRNA transcripts were detected in the vascular
smooth muscle and in the alveolar walls cells [12]. During
foetal lung development, while in vivo, both in normal and
hypertensive ovine foetuses the enzyme was only detected
in the vascular wall [14]; in vitro, on the other hand, a
hyperoxia-inducible expression of PDE5 mRNA and protein
was shown in foetal pulmonary artery smooth muscle cells
[23].
We decided to investigate the PDE5 expression in diﬀer-
ent cell populations of the developing rat lung, utilising an
aﬃnity puriﬁed polyclonal antibody, raised against the N-
terminal region of bovine PDE5 [21], revealed by either the
conventional or the ampliﬁed ABC immunohistochemical
procedure [24]. We examined paraﬃns e c t i o n so fl u n g
parenchyma from animals at developmental stages com-
prised between the embryonic day 15.5th and the postnatal
day14th.Moreover,inordertoprovideadetaileddescription
of the cell populations that speciﬁcally express PDE5 inside
the intersaccular walls in early postnatal development, we
studied possible colocalization of PDE5 with the cytoskeletal
markers α-smooth muscle actin (α-SMA) and/or desmin.
2.MaterialandMethods
2.1. Animals. Albino Wistar rats (Charles River, Italy)kept at
20–22
◦C,withadark/lightcycleof12/12hours.Femaleswere
placed with males overnight and examined the following
morning for the presence of sperm in the vaginal smear; the
sperm observation day was considered as the embryonic day
0.5th (E0.5). Animals were housed and handled according to
the European Communities Council Directive of November
24th 1986 (86/609/EEC) and to the Italian Health Ministry
guidelines.
2.2. Fixation and Tissue Processing. Pregnant rats at gesta-
tional age E15.5 and E17.5 were i.p. injected with Farmotal
(Amersham Pharmacia Biotech Italia, Cologno Monzese,
Milan, Italy) 100mg/kg b.w.; the uterus was quickly removed
and immersed in Ringer’s solution, individual embryos were
extracted from the decidua and ﬁxed by immersion in
Bouin, for 4 hours at room temperature (RT). Foetal ages
were conﬁrmed basing on weight and length. 10 minutes
after immersion in ﬁxative, the embryos were cut along the
sagittal plane. Rats aging 3, 7 and 14 days (at least four
animals for each developmental stage) were i.p. injected with
Farmotal 100mg/kg b.w. and were endotracheally instilled
with 50–80μL of Bouin’s or Methacarn’s solutions. The
dose of ﬁxative was chosen on the basis of preliminary
experiments. Trachea was then ligated; lungs were removed
and immersed in the same solutions. A few minutes later,
lungs were cut in fragments, which were further ﬁxed for
2–4 hours. All specimens were dehydrated, embedded in
paraﬃn, and sectioned 7μm thick; at least three embryos
for each gestational age and several randomly chosen
lung samples taken from 3, 7, and 14 day-old rats were
utilised for immunolocalisation of PDE5 and cytoskeletal
markers.
Concerning the immunolocalisation of cytoskeletal pro-
teins, since a stronger labelling was found after Methacarn
ﬁxation with respect to Bouin, the identiﬁcation of cells
coexpressing PDE5 and α-SMA or PDE5 and desmin was
carried out in serial sections obtained from Methacarn-ﬁxed
lungs.
2.3. Anti-PDE5 Antibody Production and Puriﬁcation. As
previously described in [21], a speciﬁc PDE5 antiserum
was produced in rabbits using as immunogen a fusion
protein containing glutathione S-transferase and a peptide
corresponding to the 68–239 amino acid residues of the N-
terminal bovine lung PDE5 sequence. After puriﬁcation by
aﬃnitychromatographyonaproteinAcolumnthisantibody
was able to immunoprecipitate cGMP-PDE activity from
mouse tissues.
The activity recovered in the immunoprecipitate was
identiﬁed as PDE5 on the basis of its sensitivity to the spe-
ciﬁc inhibitors zaprinast (IC50 0.6μM) and sildenaﬁl (IC50
4nM). Moreover, western blotting of the immunoprecipitate
showed three speciﬁc immunoreactive bands (100, 93, and
86kDa), corresponding to known PDE5 splice variants [25].
2.4. Western Blot Analysis. Lung samples from adult and
suckling rats were homogenized in 20 mM Tris-HCl buﬀer,
pH 7.2, containing 0.2mM EGTA, 5mM mercaptoethanol,
1mM PMSF , 5mM MgCl 2, and 2% (v/v) antiprotease
cocktail, using a glass homogenizer (15 strokes, 4◦C).
Homogenates were centrifuged at 14 000 x g for 30 minutes
at 4◦C, and pellets were resuspended in the homogenization
buﬀer and centrifuged at 14 000 x g for 30 minutes (4◦C).
The ﬁrst and second supernatants were then pooled and
denatured for an SDS-Page run. Protein determination
was performed using the procedure of Lowry [26]. SDS-
polyacrylamide gel electrophoresis was performed on 10%
slab gels according to Laemmli [27], and proteins were
then transferred to nitrocellulose membranes according to
Towbin et al. [28]. The blots were incubated for 3 hours
at RT with 1:1000 rabbit polyclonal anti-PDE5 and mouse
monoclonal antiactin antibodies (Sigma Chemical Co., St.
Louis, USA); actin band was used as reference protein in
densitometric evaluation. In competition experiments, the
incubation medium was supplemented with 10μg/mL of
the PDE5-peptide antigen used to raise PDE5 antibody.Journal of Biomedicine and Biotechnology 3
Alkaline phosphatase-conjugated goat, antirabbit and anti-
mouse IgG were used to reveal immunocomplexes. The
bands were then stained with nitro-blue tetrazolium in
the presence of 5-bromo-4-chloro-3-indolyl-phosphate. A
crude extract of N18TG2 cells, which are known to highly
express PDE5 [21], was utilised as a positive control.
Densitometric analysis on scanned blots was performed
using the NIH ImageJ v1.29 program; the signiﬁcance of
diﬀerences was evaluated by means of variance analysis
(ANOVA).
2.5. Immunohistochemistry. Freshly deparaﬃnized sections
were treated with 0.3% H2O2 in methanol, for 30 minutes at
RT, to inactivate endogenous peroxidases; after rehydration
they were transferred to PBS containing 0.2% Triton X-100
and5%nonfatdrymilk,for1houratRT,andthenincubated
for24hoursat4◦C,intheprimaryantibodies,dilutedinPBS
containing 0.1% Triton X-100 and 2.5% nonfat dry milk.
Dilutions were: 1:200 rabbit polyclonal anti-PDE5;
1:300 mouse monoclonal antihuman muscle actin (Dako,
Carpinteria, CA, USA); 1:800 mouse monoclonal anti-α-
SMA (Sigma Chemical Co., St. Louis, USA); 1:100 mouse
monoclonal antidesmin (Sigma Chemical Co., St. Louis,
USA).
For the revelation of immunocomplexes through the
conventional ABC method, sections were sequentially incu-
bated in
(i) 1:200 biotinylated goat antirabbit or rabbit anti-
mouse IgG, for 1 hour at RT,
(ii) avidin-biotin-horseradish peroxidase complex, for 1
hour at RT,
(iii) 0.05% 3,3’-diaminobenzidine (DAB) in PBScontain-
ing 0.01 H2O2 for 2–5 minutes at RT, in the ampliﬁed
ABC procedure the step (ii) was followed by
(i) incubation in biotinylated tyramine, 1:100
diluted in PBS containing 0.01 H2O2 for 10
minutes at RT,
(ii) avidin-biotin-horseradish peroxidase complex,
for 30 minutes at RT.
Microwave treatment was carried out incubating freshly
rehydrated sections with citrate buﬀer pH 6 (10 minutes
a tR T ,8m i n u t e si nt h em i c r o w a v eo v e na t7 5 0 W ,a n d3 0
minutes at RT).
For negative control, the primary antibody was omitted
or substituted with preimmune serum. Moreover, some
sections were incubated with the anti-PDE5 antibody pread-
sorbed (overnight at 4◦C) with 150μg/mL of the PDE5-
peptide utilised as immunogen [21].
Unstained and haematoxylin counterstained sections
were examined in a Zeiss Axioskop2, equipped with a video
camera. Representative images were electronically captured;
contrast and brightness were adjusted via Adobe Photoshop
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Figure 1: PDE5 expression at diﬀerent stages of rat lung develop-
ment. Upper panel: representative western blot analysis of adult
lung (ALu), 14 day-old lung (P14Lu), 3 day-old lung (P3Lu),
adult lung incubated in presence of PDE5-peptide (ALu+peptide).
N18 cell culture (N18) was utilised as standard of PDE5. Each
lane was loaded with 50μg of protein. Lower panel: densitometric
quantiﬁcation of immunoreactive PDE5 and actin bands. Data
are mean ± SD of 3 diﬀerent experiments. Diﬀerences were not
signiﬁcant (ANOVA test).
3. Results
3.1. Western Blot Analysis. As shown in Figure 1,b o t h
lung preparations and neuroblastoma N18TG2 cell extract
showed the strong bands at 100kDa, corresponding to the
PDE5 main splicing variant; the less intense bands, detected
at lower molecular masses (93 and 86kDa), were identiﬁed
as corresponding to other known splice variants [25].
The absence of reactivity shown by the sample incubated
in peptide-supplemented medium conﬁrmed the antibody
speciﬁcity. All these results are in agreement with previous
data obtained in experiments on mice [21]. Quantitative
examination, carried out using actin as referenceprotein, did
not reveal signiﬁcant diﬀerences among the three lung sam-
ples taken at diﬀerent developmental stages (Figure 1(b)).
3.2. PDE5 Immunohistochemistry. With all the techniques
employed (Bouin or Methacarn ﬁxations, microwave treat-
ment against nonmicrowave treatment, standard or ampli-
ﬁed ABC methods), at every stage we examined, PDE5
immunoreactivity was restricted to the cytoplasmic com-
partment of speciﬁc cell types. Sections incubated with
preimmune serum instead of the primary antibody, as well
as those incubated with the antibody pre-adsorbed with the
p e p t i d eu t i l i s e da sa ni m m u n o g e n ,w e r ef r e eo fl a b e l l i n g .
In all the examined developmental stages, the epithelium
of the airways was unlabelled, while a mild staining was
found in the smooth muscle of speciﬁc parts of the4 Journal of Biomedicine and Biotechnology
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Figure 2: Rat lung. Bouin ﬁxation. PDE5 immunohistochemistry carried out via the ampliﬁed ABC method on microwave treated sections.
Haematoxylin counterstaining. (a) E15.5, (b) E17.5, (c) P3, (d) P7, (e) P14. s: saccule; a: alveolus; c: canalicular portion of the respiratory
space; TB terminal bronchiole; LB larger bronchiole. ((a), (b)) Bar 20μm; ((c), (d), (e)) Bar 50μm. ((a), (b)) positivity is restricted to the
cytoplasm of several cells, the majority of which are scattered in the stroma (arrowheads), while some are closely apposed to the respiratory
tubule (arrows). The tubular epithelium is unlabelled. ((c), (d), (e)) labelling is restricted to the distal parenchyma, including sacculi, alveoli,
and canalicular portions of respiratory spaces. The epithelium of terminal bronchioles is unstained.
respiratory tree (e.g., major airways in embryos, larger
bronchioles in suckling rats). Vascular myocytes were very
mildly labelled, and their staining intensity changed with
respect to the ﬁxation and incubation conditions, reaching
total negativity in Methacarn-ﬁxed specimens.
Both in pre- and in postnatal lungs, the heaviest PDE5-
positivity was shown in cells located in the pulmonary
stroma. In embryos, both at pseudoglandular (E15.5) and
at canalicular (E17.5) phases of lung development (Figures
2(a) and 2(b)), these strongly labelled cells were numerous
and randomly distributed, with only some closely adhering
to the epithelial wall.
In suckling rats (Figures 2(c), 2(d), and 2(e)), heavily
labelled stromal cells were especially abundant in the walls
of distal respiratory spaces (sacculi and alveoli depend-
ing on developmental stage); concerning larger airways, a
mild staining was present in the muscular layer of larger
bronchioles,whileterminalbronchiolesappearedunlabelled.
Neither number nor position of PDE5-expressing cells
remarkably changed among the examined developmental
stages.
3.3. Immunohistochemistry of Cytoskeletal Proteins. In all
the examined specimens, independently from the diﬀerent
ﬁxation and incubation conditions, at every examined stage
the immunoreactivity for total actin, α-SMA, and desmin
wasrestrictedtothecytoplasmiccompartmentofspeciﬁccell
types; all control sections were free of labelling. Concerning
the strength of labelling, the best results were obtained with
Methacarn-ﬁxed, nonmicrowave-treated specimens.
Throughout the examined postnatal development the
cytoskeletal markers were immunolocalised in muscle cells
belonging to bronchial, bronchiolar, and vessel walls as
well as in those underlying the epithelia in the canalicular
portions of the respiratory spaces; epithelia were always
unlabelled, while a speciﬁc labelling was additionally found
in the cytoplasmic compartment of many cells of the
intersaccular walls. All control sections were free of labelling.
Concerning the distribution of positivity in the intersac-
cular wall, at 3, 7, and 14 days of postnatal development: (i)
total actinexpressing cells were relatively few and randomly
distributed inside the interstitium; (ii) desmin-containing as
well as α-SMA-positive cells were sensibly more numerous;
moreover, they were preferentially found in close proximityJournal of Biomedicine and Biotechnology 5
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Figure 3: Rat lungs. Postnatal day 3. Methacarn ﬁxation.
Immunolocalisation of diﬀerent markers, carried out in adjacent
sections. Standard ABC method. Haematoxylin counterstaining. s:
saccule; c: canalicular portion of respiratory space; v: vessel. Bar
20μm. (a) α-SMA immunolocalisation. Besides what found in the
vascular wall, a strong labelling is found in the myocytes adhering
to the epithelium in the canalicular portions of respiratory spaces,
as well as in cells located in the intersaccular walls. (b) PDE5
immunolocalisation. The labelling is restricted to the cytoplasm of
several stromal cells, located in close proximity with the saccular
boundary. The myocytes of the small vessel and of respiratory
channels are unstained. (c) desmin immunolocalisation. Both the
myocytes in the canalicular portions of respiratory spaces and those
belonging to the vessel wall are strongly labelled; moreover few
labelledcellsarescatteredintheintersaccularwalls.Arrowsindicate
some α-SMA- or desmin-containing PDE5-positive cells.
to the respiratory epithelium, especially on the tip of the
intersaccular septa, and around the venules at the junctions
of the three septa.
At all the examined stages, the number and distribution
of PDE5-expressing cells appeared substantially similar to
those of α-SMA-containing cells, while the correspondence
was weaker with desmin-containing elements. Finally, only
rare and randomly located stromal cells showed the contem-
porary presence of PDE5 and total actin. The developmental
stage of P3 was chosen as the most suitable for validating
these preliminary results, and serial sections taken from 3
day-old animals were therefore submitted the immunolo-
calisation of PDE5, α-SMA, and desmin. Figure 3 shows
a representative ﬁeld, where several PDE5-expressing cells,
located in the saccular wall, are found to correspond to α-
SMA-containing elements, while a lower number is found
to express desmin; fewer cells appear to express all three
markers at the same time.
4. Discussion
PDE5-immunolocalization experiments revealed that in pre-
and postnatal rat lungs stromal cells located in the inter-
stitium between the respiratory units mainly expressed the
enzyme. More in particular, during pseudoglandular and
canalicular phases of prenatal lung development, PDE5-
expressing cells showed a preferential position close to
the tubular epithelium, while during the saccular phase
of postnatal lung development they were exclusively found
in the wall of distal respiratory spaces (canaliculi, sacculi,
alveoli).
Concerning lung airways and vessels in the respiratory
tree, PDE5 immunoreactivity was always absent in epithe-
lium and hardly detectable in muscle of larger bronchioles,
while vascular myocytes were very mildly labelled and their
staining intensity changed with respect to ﬁxation and
incubation conditions.
Discrepancies between our results and those reported
by other authors who found stronger PDE5 expression
in vascular walls during perinatal development [11, 12]
might be due to diﬀerences in the experimental method (in
situ hybridization instead of immunohistochemistry) and
adopted species (sheep instead of rats).
The high level of PDE5 expression shown in suckling
rat lungs by nonvascular cells of distal parenchyma supports
the previously suggested idea [12] that in perinatal lung
the NO/cGMP signal transduction system might play key
roles not only in the regulation of vascular resistance but
more generally in tissue remodelling. In immature rodent
lungs the angiogenic factor VEGF is known to induce
endothelialproliferationanddiﬀerentiationthroughbinding
to Flk-1 [29], highly expressed by endothelial cells closely
apposed to the developing epithelium [30, 31]. According to
results obtained in other experimental models [32, 33], we
argue that in immature lungs, Flk-1-bound VEGF stimulates
endothelial nitric oxide synthase, with consequent nitric
oxideproduction.NO/cGMPsystemandcGMPmodulation,
therefore, appear to be crucial steps in pulmonary angiogen-
esis.
Concerning the cell types that speciﬁcally express PDE5
in neonatal rat lungs, we found that many of them also
contain α-SMA, while some expressing desmin; on the
other hand only few cells express all the three markers at
the same time. According to recent literature [34], the α-
SMA+/desmin- cells mainly include interstitial myoﬁbrob-
lasts,withacontributeoftransitionalpericytesboundtopre-
and postcapillary microvascular segments [35, 36], while
the α-SMA-/desmin+ cells are presumed to be interstitial
lipoﬁbroblasts.
Itisworthremindingthatα-SMA-containingmyoﬁbrob-
lasts, which in adult lung are only detected during idio-
pathic or bleomycin-induced ﬁbrosis [37, 38], in perinatal6 Journal of Biomedicine and Biotechnology
developmentshowincreasedα-SMAexpressionandcollagen
synthesis, together with cytoskeletal reorganization, and are
presumed crucial for adaptation to extra uterine life [39].
On the basis of our data concerning PDE5 expression
in myoﬁbroblasts and pericytes and in agreement with
results obtained in liver and kidney samples (in which the
nonselective phosphodiesterase inhibitors pentoxifylline and
3-isobutyl-1-methylxanthinewerefoundtoreducebothpro-
liferation rate and collagen secretion of α-SMA-expressing
myoﬁbroblasts [40–42]), we argue that in neonatal mam-
malian lung the NO/cGMP signal transduction system,
besides being involved in vessel maturation, inﬂuences
homeostasis and ﬁbrogenic activity of myoﬁbroblasts.
Structural and functional modiﬁcations of myoﬁbrob-
lasts and pericytes, which are both responsible for the
tensile ﬁne tuning of capillaries and compliance of inter-
airspace walls [43, 44], might constitute the basis for
the alterations in extracellular matrix deposition, septal
elongation and alveolar maturation found, for example,
in hyperoxia-induced pulmonary perinatal hypertension.
Interestingly, in this experimental condition sildenaﬁl was
found to increase lung capillary density and to preserve
alveolar growth [17]. In conclusion the possible eﬀects of
PDE5 inhibitors on diﬀerent pulmonary cell types should
be accurately investigated, in order to better utilise these
substances as therapeutic agents in neonatal chronic lung
diseases characterised by excess matrix deposition.
Abbreviations
PDE5: cGMP-binding cGMP-speciﬁc phosphodiesterase.
a-SMA: a-smooth muscle actin.
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